LAG3 and neoplasm: In an in vitro functional analysis of allogeneic T cells, the combination of REGN3767 (anti-LAG-3) with cemiplimab (REGN2810, anti-PD-1) increased T-cell activation, the proportion of effector T cells in the tumor and intratumoral CD4+ and CD8+ T cells producing IFN-γ, TNF-α, and IL-10 levels in the blood and spleen to reduce tumor growth [47].